The U.S. Food and Drug Administration (FDA) approved the chimeric antigen receptor T-cell (CAR-T) therapy, a new therapy for a type of lymphoma, developed by Gilead Science’s acquired unit Kite Pharma. This marks the second approval for the potentially groundbreaking approach to fighting cancer after FDA approved Novartis’ Kymriah in August.

Gilead Sciences acquired Kite Pharma for $11.9 billion in August, which it completed on October 3.